Abstract: A method for preparing a conjugate by linking a physiologically active polypeptide, a non-peptidyl polymer linker, and an immunoglobulin constant region via a covalent bond are disclosed. The method enables an efficient preparation of a physiologically active polypeptide conjugate, in which a salt is used in a coupling reaction to improve the problem of low production yield during preparation of the physiologically active polypeptide conjugate.

Abstract: The present invention relates to a fusion protein between a therapeutic enzyme and an immunoglobulin Fc region, a method thereof, and a composition comprising the fusion protein.

Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.

Abstract: Provided is an ophthalmic pharmaceutical composition having a certain pH, comprising aflibercept as an active ingredient and an acetate salt buffering agent, wherein the composition is free of an ionic tonicity agent, remarkably reduces the formation of dimeric and multimeric impurities, and maintains the biological activity in a high level for a long time, under the accelerated and stress conditions as well as under the cold storage condition.

Abstract: The present invention relates to a dry powder inhaler. The dry powder inhaler includes an inhaler housing, a drug container configured to be provided in the inhaler housing and accommodate the dry powder drug, a drug inlet configured to be disposed above the drug container and through which the dry powder drug is inhaled, and a mesh network configured to be installed on a path of the drug inlet and have a mesh part for collision with the dry powder drug formed therein.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.

Abstract: Provided are crystalline form A of rebaudioside D, and a preparation method and application therefor. In X-ray powder diffraction analysis measured using Cu-K? rays and with 2? being expressed in degrees, crystalline form A of rebaudioside D has significant characteristic diffraction peaks at least at 4.53, 6.38, 12.76, 13.52, 17.48, 17.96, 20.07 and 22.63. The preparation method is a suspension method, a solvent evaporation method or a cooling method. The preparation method has a simple process, and is convenient to operate. A rebaudioside D crystalline form A product has a good degree of crystallinity, good water solubility, and high chemical stability.

Abstract: The present invention relates to an insulin analog conjugate and use thereof.

Abstract: The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition containing: adherent cells originating from mesenchymal tissue that has been treated with a physiologically active polypeptide or an LPS; and a pharmaceutically acceptable carrier.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: The present invention relates to a conjugate of a physiologically active polypeptide and immunoglobulin Fc with attenuated immune response, a method for preparing the conjugate, a composition for reducing an immune response including the conjugate, and a method for reducing the immune response of the physiologically active polypeptide. Further, the present invention relates to a method for maintaining the reduction in the intrinsic binding affinity of the conjugate for an Fc gamma receptor and/or a complement, and a composition including the conjugate.

Abstract: The present invention relates to the technical field of chemical drugs and crystal form processes, and to a pyrroloquinoline quinine B crystal form and a preparation method therefor. The present invention comprehensively characterizes the pyrroloquinoline quinine B crystal form by virtue of means such as X-ray powder diffraction analysis, thermo-gravimetric analysis, and differential scanning calorimetry analysis so as to find the fact that the pyrroloquinoline quinine B crystal form is high in crystallinity and low in hygroscopicity, and a regular crystal form can be formed, thereby facilitating process treatment and improvement of physical and chemical properties of a medicine, and improving the patent medicine performance. The preparation method for the pyrroloquinoline quinone B crystal form provided in the present invention is simple, easy to control, and high in reproducibility.

Abstract: In one aspect, a composition for topical application is provided. The composition comprises a base. Dispersed within the base is elemental silver as a colloidal suspension, and plant extract from at least 6 plants. The plants are selected from the group consisting of Echinacea purpurea, Stellaria media, Aloe vera, Matricaria recutita, Hypericum perforatum, Calendula officinalis, Equisetum arvense, Symphytum officinale, Panax ginseng, Rumex crispus, Arctium lappa, Trifolium pratense, Chelidonium majus, Thuja occidentalis, Urtica dioica, Mahonia aquifolium, and Galium aparine.

Abstract: Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Abstract: A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

Abstract: A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

Abstract: Disclosed is a method of preparing an intermediate for an oxazolidinone derivative, which enables 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine to be produced at high yield and high purity, thus exhibiting high preparation efficiency under optimal processing conditions and making it suitable for industrial mass production.

Abstract: A method for cultivating Monarda fistulosa for production of thymoquinone includes planting seeds at rates between about 2.5 and about 5 pounds per acre, preferably about 4 pounds per acre. The heavy rate of planting produces plants bearing oil without weed contamination and reduces herbicide use due to production of natural herbicides by the monarda plants. Seeding and mowing the first season, and harvesting in seasons thereafter reduce costs. The method results in increased production of essential oils including thymoquinone and thymohydroquinone at levels up to about 40% or more of recovered oils, and which may be distilled from the plant.

Abstract: The present invention relates to a composition for neuroprotection comprising a phenyl carbamate compound and a method for providing neuroprotection therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases associated with neurological injury.